Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
27
Frequently Asked Questions
What is Market Cap of Kinnate Biopharma Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Kinnate Biopharma Inc market cap is $125.15M.
What is the 52-week high for Kinnate Biopharma Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Kinnate Biopharma Inc 52 week high is $6.00 as of September 28, 2025.
What is the 52-week low for Kinnate Biopharma Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Kinnate Biopharma Inc 52 week low is $1.04 as of September 28, 2025.
What is Kinnate Biopharma Inc stock price today?
Kinnate Biopharma Inc stock price today is $2.65.
What was Kinnate Biopharma Inc stock price yesterday?
Kinnate Biopharma Inc stock price yesterday was $2.66.
What is the PE ratio of Kinnate Biopharma Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Kinnate Biopharma Inc’s P/E ratio is -1.09.
What is the Price-to-Book ratio of Kinnate Biopharma Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Kinnate Biopharma Inc P/B ratio is 0.7838.
What is Kinnate Biopharma Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Kinnate Biopharma Inc's EBITDA is 0.33.
What is the 50-day moving average of Kinnate Biopharma Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Kinnate Biopharma Inc 50-day moving average is $2.52.
How many employess does Kinnate Biopharma Inc has?
